TG Therapeutics (TGTX) CEO On Approaching Cancer Treatments

<p>Michael Weiss explains TG Therapeutics cancer drugs with expected PDUFA dates. He says they have a&nbsp;multiple sclerosis drug with a target approval for mid-year 2022. He says their R&amp;D expense has come down and they have $600 million in cash as of the end of the year.</p>